Literature DB >> 14643961

Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer.

Carlo Greco1, Chiara Mazzetta, Federica Cattani, Giampiero Tosi, Simona Castiglioni, Andrei Fodor, Roberto Orecchia.   

Abstract

BACKGROUND AND
PURPOSE: The rectum is known to display a dose-volume effect following high-dose 3D-conformal radiotherapy (3D-CRT). The aim of the study is to search for significant dose-volume combinations with the specific treatment technique and patient set-up currently used in our institution. PATIENTS AND METHODS: We retrospectively analyzed the dose-volume histograms (DVH) of 135 patients with stage T1b-T3b prostate cancer treated consecutively with 3D-CRT between 1996 and 2000 to a total dose of 76 Gy. The median follow-up was 28 months (range 12-62). All late rectal complications were scored using RTOG criteria. Time to late toxicity was assessed using the Kaplan-Meyer method. The association between variables at baseline and > or=2 rectal toxicity was tested using chi(2) test or Fisher's exact test. A multivariate analysis using logistic regression was performed.
RESULTS: Late rectal toxicity grade > or=2 was observed in 24 of the 135 patients (17.8%). A 'grey area' of increased risk has been identified. Average DVHs of the bleeding and non-bleeding patients were generated. The area under the percent volume DVH for the rectum of the bleeding patients was significantly higher than that of patients without late rectal toxicity. On multivariate analysis the correlation between the high risk DVHs and late rectal bleeding was confirmed.
CONCLUSIONS: The present analysis confirms the role of the rectal DVH as a tool to discriminate patients undergoing high-dose 3D-CRT into a low and a high risk of developing late rectal bleeding. Based on our own results and taking into account the data published in the literature, we have been able to establish new dose-volume constraints for treatment planning: if possible, the percentage of rectal volume exposed to 40, 50, 60, 72 and 76 Gy should be limited to 60, 50, 25, 15 and 5%, respectively.

Entities:  

Mesh:

Year:  2003        PMID: 14643961     DOI: 10.1016/j.radonc.2003.08.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.

Authors:  Pilar M Samper; M Concepción López Carrizosa; Ana Pérez Casas; Carmen Vallejo; M Carmen Rubio Rodríguez; Consuelo Pérez Vara; Miguel Melchor Iñiguez
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

2.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

3.  Planning study to compare dynamic and rapid arc techniques for postprostatectomy radiotherapy of prostate cancer.

Authors:  R Cambria; F Cattani; B A Jereczek-Fossa; F Pansini; D Ciardo; S Vigorito; S Russo; D Zerini; L Cozzi; R Orecchia
Journal:  Strahlenther Onkol       Date:  2014-02-21       Impact factor: 3.621

4.  Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.

Authors:  Susan L Tucker; Lei Dong; Jeff M Michalski; Walter R Bosch; Kathryn Winter; James D Cox; James A Purdy; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

5.  Physical and clinical implications of radiotherapy treatment of prostate cancer using a full bladder protocol.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Dario Zerini; Federica Cattani; Flavia Serafini; Rosa Luraschi; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2011-11-25       Impact factor: 3.621

6.  Dosimetric impact in the dose-volume histograms of rectal and vesical wall contouring in prostate cancer IMRT treatments.

Authors:  Laura Gómez; Carlos Andrés; Antonio Ruiz
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-21

7.  Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  B A Jereczek-Fossa; A Maucieri; G Marvaso; S Gandini; C Fodor; D Zerini; G Riva; O Alessandro; A Surgo; S Volpe; G Fanetti; S Arculeo; M A Zerella; S Parisi; P Maisonneuve; A Vavassori; F Cattani; R Cambria; C Garibaldi; A Starzyńska; G Musi; O De Cobelli; M Ferro; F Nolè; D Ciardo; R Orecchia
Journal:  Med Oncol       Date:  2018-11-27       Impact factor: 3.064

Review 8.  Gastrointestinal radiation injury: prevention and treatment.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer.

Authors:  Markus Bohrer; Peter Schröder; Grit Welzel; Hansjörg Wertz; Frank Lohr; Frederik Wenz; Sabine Kathrin Mai
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

10.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.